I personally think CIIX could go way higher then this price projection if skin care line takes off
Last Updated: July 31, 2017
Ludlow Research Initiates Coverage on CIIX with Short-Term Valuation Target of $1.50 to $2.00 Per Share
(NEW YORK) – Ludlow Research initiated coverage on ChineseInvestors.com, Inc. (OTCQB: CIIX), a portfolio of consumer-packaged goods and brands, with a ‘speculative’ short-term target of $1.50 to $2.00 per share based on their pending launch of their 'CBD Magic Hemp Series' skin care product in China.
Files with China’s FDA
The Company recently announces that its wholly-owned foreign enterprise, CBD Biotechnology Co. Ltd., has officially filed a record of its first line of non-industrial hemp-infused skin care products with the China Food and Drug Administration (CFDA).
Pending Product Launch
The new 'CBD Magic Hemp Series' skin care line is expected to launch between late August and early September 2017, positioning CBD Biotechnology as a first-mover in an untapped segment of China's skin care industry.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.